MindMed Gears Up for Key Presentation at J.P. Morgan Healthcare Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a pioneering late-stage clinical biopharmaceutical company focused on brain health disorders, has officially announced its participation in the prestigious 44th Annual J.P. Morgan Healthcare Conference. Scheduled for January 14, 2026, in San Francisco, the event will feature insights from Rob Barrow, the company’s Chief Executive Officer, at 2:15 p.m. PT. This presentation marks a significant opportunity for MindMed to showcase its advancements and strategic direction as it approaches a pivotal year.

Rob Barrow expressed enthusiasm about the upcoming conference, stating, “It is a privilege to participate in the J.P. Morgan Healthcare Conference as we continue to share the progress MindMed is making to forge a new era of psychiatry.” His remarks underscore the company’s commitment to innovation in mental health treatments, particularly as it prepares for what it anticipates will be a transformative year.

MindMed is on the brink of significant developments, with three critical Phase 3 topline readouts on the horizon. The outcomes of these readouts are crucial as they may lead to potential submissions to the U.S. Food and Drug Administration (FDA) for two of the largest psychiatry markets: Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). These markets represent a considerable opportunity for MindMed, positioning the company at the forefront of psychiatric treatment innovations.

The J.P. Morgan Healthcare Conference serves as a vital platform for MindMed to engage with the investment community. The event is known for its high-profile attendance and discussions surrounding the future of healthcare and biopharmaceuticals. MindMed’s participation signals the company’s intent to communicate its progress and strategic vision directly to investors and stakeholders, fostering transparency and potential investment interest.

For those unable to attend the live presentation, a webcast will be available, allowing investors and other interested parties to access the information conveniently. The audio replay will be available 24 hours after the live event and will remain active on MindMed’s website for 30 days, ensuring that a broader audience can stay informed about the company’s developments.

MindMed is dedicated to the development of novel product candidates aimed at treating brain health disorders. The company’s mission centers on becoming a global leader in delivering innovative treatments that can significantly enhance patient outcomes. With a robust pipeline targeting neurotransmitter pathways critical to brain health, MindMed is well-positioned to make meaningful contributions to the field of psychiatry.

The company's stock is publicly traded on NASDAQ under the symbol MNMD, allowing investors to participate in its growth journey as it navigates the challenges and opportunities in the biopharmaceutical landscape.

As MindMed prepares for its presentation at the J.P. Morgan Healthcare Conference, all eyes will be on the company’s progress in advancing treatments for mental health disorders. With pivotal Phase 3 readouts on the horizon and a commitment to innovation, MindMed is setting the stage for what could be a groundbreaking year in psychiatry. Investors and stakeholders alike will be closely monitoring the developments as they unfold, eager to see how MindMed’s advancements could reshape the future of mental health treatment.